Company Overview - Anixa Biosciences, Inc. (NASDAQ: ANIX) focuses on developing immunotherapies for cancer through two main platforms: a CAR-T program aimed at solid tumors and a vaccine technology that generates tumor-specific antigens [1]. Partnerships - Anixa has established partnerships with the Moffitt Cancer Center, which may enhance its research and development capabilities in the field of cancer immunotherapy [1].

Group 1: Stock Performance - Novavax (NVAX) closed at $6.97, with a daily increase of +1.9%, outperforming the S&P 500's gain of 0.14% [1] - Over the last month, Novavax shares decreased by 1.44%, while the Medical sector lost 1.34% and the S&P 500 gained 3.97% [1] Group 2: Upcoming Earnings - The upcoming EPS for Novavax is projected at -$0.12, indicating a 112.12% decline compared to the same quarter last year [2] - Revenue is estimated at $130.5 million, reflecting a 68.59% decrease from the corresponding quarter of the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $2.65 per share, representing a +315.45% change from the previous year [3] - Revenue for the fiscal year is estimated at $1.07 billion, indicating a +56.76% change from the prior year [3] Group 4: Analyst Estimates and Rankings - Recent modifications to analyst estimates for Novavax indicate changing near-term business trends, with positive revisions suggesting optimism [4] - The Zacks Rank system, which includes estimate changes, currently ranks Novavax at 3 (Hold) [6] Group 5: Valuation Metrics - Novavax has a Forward P/E ratio of 2.58, which is a discount compared to the industry average Forward P/E of 18.51 [7] - The PEG ratio for Novavax is 0.06, significantly lower than the industry average PEG ratio of 1.54 [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Novavax, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [8][9] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9]

Vaccine Recommendations & Insurance Coverage - Removing recommendations may impact patient choice, especially for vulnerable populations who rely on no-cost vaccines linked to CDC and ASIP recommendations [1][3] - Insurance companies have individual policies, some may not cover important treatments [2] - Various programs (private insurers, employer-sponsored plans, Medicare Part D, Medicaid, Vaccines for Children) link no-cost vaccines to CDC/ASIP recommendations [3] FDA's Role & Vaccine Safety - FDA's role is to assess the safety and effectiveness of submitted applications [4] - Concerns raised about potential loss of trust in the FDA due to policies perceived as "rubber stamping" vaccines without sufficient evidence, particularly for young, healthy individuals [5] - Industry emphasizes the need for strong evidence when recommending interventions, especially for new viruses and vaccines [5] - Clinical trial results in children were mixed four years ago [6]

Join the club today. Go to CNBC. com.>> Our newsmaker this hour. Doctor Marty Makary the FDA commissioner marking his first 100 days on the job. It's been a busy few months with many changes at the agency from vaccines to staffing.Good morning doctor. >> Good morning Joe. I don't.>> Know, maybe you've been on a few times. I don't remember, but we all went through that, that period together, obviously. And there's a lot of look back now at, at that period.I was you know it's a hot button issue and sometimes ...

Our newsmaker this hour, Dr. . Marty McCary, the FDA commissioner, marking his first 100 days on the job. It's been a busy few months with many changes at the agency from vaccines to staffing.Good morning, uh, doctor. Good morning, Joe. I don't maybe you've been on a few time.I don't I I don't remember, but we all went through uh that that period together, obviously, and and there's a lot of u of of a look back now at at at that period. you know, it's, you know, it's a it's a hot button issue and sometimes ...

Core Insights - Evaxion A/S has finalized an agreement with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into equity, enhancing its capital structure and financial flexibility [1][2][6] Group 1: Financial Impact - The conversion involves EIB purchasing ordinary Evaxion warrants at a price of $4.87, which represents a premium of 89% over the share price at market close yesterday [2][6] - This agreement immediately increases Evaxion's equity by $4.1 million (€3.5 million), while also substantially reducing overall liabilities and simplifying the balance sheet [2][6] Group 2: Management Commentary - The CFO of Evaxion, Thomas F. Schmidt, expressed satisfaction with the favorable terms of the agreement, highlighting its importance for cash flow and financial management [3]

Group 1: Canopy Growth - Canopy Growth has been a disappointing investment over the past five years, with a significant decline in net revenue and increased losses per share [3][4] - The cannabis industry faces challenges such as legal and regulatory issues, competition from illicit markets, and oversupply, particularly in Canada [5][6] - Despite cost-cutting efforts and a focus on in-demand products, the long-term outlook for Canopy Growth remains bleak, with expectations of further stock decline [6][7] Group 2: Novavax - Novavax reported substantial revenue growth in the first quarter, with revenue of $666.7 million and a net income of $518.6 million, a significant improvement from the previous year [8] - The company has positive results from phase 3 studies for its influenza and combination COVID-19 vaccines, along with partnerships with major pharmaceutical companies [8][9] - However, the long-term sustainability of Novavax's performance is questionable due to market unpredictability, competition from leaders like Moderna and Pfizer, and reliance on external funding for future trials [10][12][13]

US regulators approved Moderna’s Covid vaccine for children, a positive sign for the company amid Robert F. Kennedy Jr.’s policy positions that have led to restricted access to the shots for kids https://t.co/nIBtdAkS25 ...

The American Academy of Pediatrics is suing HHS Secretary RFK Jr. . saying, quote, "We believe the children deserve better." The lawsuit alleges changes to COVID vaccine recommendations without a scientific reason. And Kennedy's firing of vaccine advisors, replacing them with multiple vaccine skeptics, are illegal and are outside established scientific practice.Joining us now, the president of the American Academy of Pediatrics, Dr. . Susan Cresley. Uh, doctor, thank you so much for joining us.Um, please ex ...

In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs: Zero vaccinated dogs developed lung lesions post H3N2 challenge2 100% neutralization of 33 currently circulating CIV field isolates1 Proven to reduce viral shedding2,5 Proven safe across multiple breed and ages in field safety study5 "With the recent USDA approval for TruCan Ultra CIV, Elanco continues to lead the charge in innovative animal health solutions," ...